Biopsy of liver metastasis for women with breast cancer: Impact on survival

Breast

Volumn 21, Issue 3, 2012, Pages 284-288

  Botteri, Edoardo ^a,b   Disalvatore, Davide ^a,c   Curigliano, Giuseppe ^a   Brollo, Janaina ^a   Bagnardi, Vincenzo ^a,c,d   Viale, Giuseppe ^a,e   Orsi, Franco ^a   Goldhirsch, Aron ^a   Rotmensz, Nicole ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c UNIVERSITY OF MILANO BICOCCA   (Italy)

^d Frontier Science and Technology Research Foundation Southern Europe   (Switzerland)

^e UNIVERSITY OF MILAN   (Italy)

Author keywords

Biopsy; Breast cancer; Liver; Metastases; Survival

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; TRASTUZUMAB;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER HORMONE THERAPY; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER METASTASIS; MAJOR CLINICAL STUDY; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 84862573558     PISSN: 09609776     EISSN: 15323080     Source Type: Journal    
DOI: 10.1016/j.breast.2011.12.014     Document Type: Article

References (28)

1. Hoe A.L., Royle G.T., Taylor I. Breast liver metastases e incidence, diagnosis and outcome. J R Soc Med 1991, 84:714-716.
2. Pivot X., Asmar L., Hortobagyi G.N., Theriault R., Pastorini F., Buzdar A. A retrospective study of first indicators of breast cancer recurrence. Oncology 2000, 58:185-190.
3. Lermite E., Marzano E., Chéreau E., Rouzier R., Pessaux P. Surgical resection of liver metastases from breast cancer. Surg Oncol 2010 Dec, 19(4):79-84.
4. Melichar B., Voboril Z., Cerman J., Melicharova K., Mergancova J., Voboril R., et al. Regional chemotherapy in patients with breast carcinoma liver metastases. Hepatogastroenterology 2006 Jan-Feb, 53(67):100-105.
5. Carrafiello G, Fontana F, Cotta E, Petullà M, Brunese L, Mangini M, et al. Ultrasound-guided thermal radiofrequency ablation (RFA) as an adjunct to systemic chemotherapy for breast cancer liver metastases. Radiol Med, in press.
6. Pagani O., Senkus E., Wood W., Colleoni M., Cufer T., Kyriakides S., et al. International guidelines for management of metastatic breast cancer: can metastatic breast cancer be cured?. J Natl Cancer Inst 2010 Apr 7, 102(7):456-463. ESO-MBC Task Force.
7. Bergenfeldt M., Jensen B.V., Skjoldbye B., Nielsen D. Liver resection and local ablation of breast cancer liver metastases - a systematic review. Eur J Surg Oncol 2011 Jul, 37(7):549-557.
8. Sharma A., Crook T., Thompson A., Palmieri C. Surgical oncology: why biopsying metastatic breast cancer should be routine. Nat Rev Clin Oncol 2010 Feb, 7(2):72-74.
9. Amir E., Clemons M. Should a biopsy be recommended to confirm metastatic disease in women with breast cancer?. Lancet Oncol 2009 Oct, 10(10):933-935.
10. Simmons C., Miller N., Geddie W., Gianfelice D., Oldfield M., Dranitsaris G., et al. Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases?. Ann Oncol 2009, 20:1499-1504.
11. Curigliano G, Bagnardi V, Viale G, Fumagalli L, Rotmensz N, Aurilio G, et al. Should liver metastases of breast cancer be biopsied to improve treatment choice? Ann Oncol, in press.
12. Gancberg D., Di Leo A., Cardoso F., Rouas G., Pedrocchi M., Paesmans M., et al. Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites. Ann Oncol 2002, 13:1036-1043.
13. Gong Y., Booser D.J., Sneige N. Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma. Cancer 2005, 103:1763-1769.
14. Zidan J., Dashkovsky I., Stayerman C., Basher W., Cozacov C., Hadary A. Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease. Br J Cancer 2005, 93:552-556.
15. Broom R.J., Tang P.A., Simmons C., Bordeleau L., Mulligan A.M., O'Malley F.P., et al. Changes in estrogen receptor, progesterone receptor and Her-2/neu status with time: discordance rates between primary and metastatic breast cancer. Anticancer Res 2009 May, 29(5):1557-1562.
16. Aitken S.J., Thomas J.S., Langdon S.P., Harrison D.J., Faratian D. Quantitative analysis of changes in ER, PR and HER2 expression in primary breast cancer and paired nodal metastases. Ann Oncol 2010, 21(6):1254-1261.
17. Amir E., Clemons M., Freedman O.C., Miller N., Coleman R.E., Purdie C., et al. Tissue confirmation of disease recurrence in patients with breast cancer: pooled analysis of two large prospective studies [Abstract]. J Clin Oncol 2010, 28:15s.
18. Arslan C., Sari E., Aksoy S., Altundag K. Variation in hormone receptor and HER-2 status between primary and metastatic breast cancer: review of the literature. Expert Opin Ther Targets 2011 Jan, 15(1):21-30.
19. Hoefnagel L.D., van de Vijver M.J., van Slooten H.J., Wesseling P., Wesseling J., Westenend P.J., et al. Receptor conversion in distant breast cancer metastases. Breast Cancer Res 2010 Sep 23, 12(5):R75.
20. Idirisinghe P.K., Thike A.A., Cheok P.Y., Tse G.M., Lui P.C., Fook-Chong S., et al. Hormone receptor and c-ERBB2 status in distant metastatic and locally recurrent breast cancer. Pathologic correlations and clinical significance. Am J Clin Pathol 2010 Mar, 133(3):416-429.
21. Chang H.J., Han S.W., Oh D.Y., Im S.A., Jeon Y.K., Park I.A., et al. Discordant human epidermal growth factor receptor 2 and hormone receptor status in primary and metastatic breast cancer and response to trastuzumab. Jpn J Clin Oncol 2011 May, 41(5):593-599.
22. Guarneri V., Giovannelli S., Ficarra G., Bettelli S., Maiorana A., Piacentini F., et al. Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases: impact on patient management. Oncologist 2008 Aug, 13(8):838-844.
23. Kirkegaard T., Edwards J., Tovey S., McGlynn L.M., Krishna S.N., Mukherjee R., et al. Observer variation in immunohistochemical analysis of protein expression, time for a change?. Histopathology 2006, 48(7):787-794.
24. Adams E.J., Green J.A., Clark A.H., Youngson J.H. Comparison of different scoring systems for immunohistochemical staining. J Clin Pathol 1999, 52(1):75-77.
25. van Diest P.J., Weger D.R., Lindholm J. Reproducibility of subjective immunoscoring of steroid receptors in breast cancer. Anal Quant Cytol Histol 1996, 18(5):351-354.
26. Rhodes A., Jasani B., Barnes D.M., Bobrow L.G., Miller K.D. Reliability of immunohistochemical demonstration of oestrogen receptors in routine practice: interlaboratory variance in the sensitivity of detection and evaluation of scoring systems. J Clin Pathol 2000, 53:125-130.
27. Pusztai L., Viale G., Kelly C.M., Hudis C.A. Estrogen and HER-2 receptor discordance between primary breast cancer and metastasis. Oncologist 2010, 15(11):1164-1168.
28. Slamon D.J., Godolphin W., Jones L.A., Holt J.A., Wong S.G., Keith D.E., et al. Studies of the HER-2 / neu protooncogene in human breast and ovarian cancer. Science 1989, 244:707-712.